Aurobindo Pharma

AUROPHARMA

INE406A01037

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 12:43:54 18/07/2024 BST			5-day change	1st Jan Change
1,336 ^INR	-2.53%		+1.40%	+23.28%

06:08am	Aurobindo Pharma to Buy Back Up to INR7.50 Billion Worth of Shares	MT
05:52am	Aurobindo Pharma Limited announces an Equity Buyback for 5,136,986 shares, representing 0.88% for INR 7,500 million.	CI

Aurobindo Pharma Limited authorizes a Buyback Plan.

July 17, 2024

The Board of Directors of Aurobindo Pharma Limited has authorized a buyback plan on July 18, 2024.

Article not found

Latest news about Aurobindo Pharma

Aurobindo Pharma to Buy Back Up to INR7.50 Billion Worth of Shares	05:08am	MT
Aurobindo Pharma Limited announces an Equity Buyback for 5,136,986 shares, representing 0.88% for INR 7,500 million.	04:52am	CI
Aurobindo Pharma Limited authorizes a Buyback Plan.	17/07/2024	CI
Aurobindo Pharma Limited's Board intends to launch an Equity Buyback on July 18, 2024.	07-14	CI
Aurobindo Pharma Arm's Injectable Facility Gets 'Voluntary Action Indicated' Classification from US FDA	06-27	MT
INDIA STOCKS-Financials weigh on Indian shares; small-, mid-caps fall	06-24	RE
Hindalco-owned Novelis delays US IPO; shares slide	06-05	RE
Aurobindo Pharma Clocks Gains in Fiscal Q4 Consolidated Net Profit	05-27	MT
Transcript : Aurobindo Pharma Limited, Q4 2024 Earnings Call, May 27, 2024	05-27
Aurobindo Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-25	CI
India's Hindalco mulls seeking $1.2 bln in Novelis IPO, Bloomberg News reports	05-08	RE
Aurobindo Pharma Limited Receives an Order from the Deputy Commissioner, Punjagutta Division, Hyderabad	05-02	CI
Aurobindo Pharma Completes Sale of US Arm's Business Assets	05-02	MT
Aurobindo Pharma Limited Announces Appointment of T. Vijaya Kumar as President R&D (Specialty Drug Delivery)	04-07	CI
Aurobindo Pharma Arms Commission Four New Plants in Andhra Pradesh, India	04-02	MT
Aurobindo Pharma Limited Announces Retirement of K. Ragunathan as Chairman of Board of Directors, Effective March 31, 2024	03-27	CI
Indian shares set to track Asian peers higher, eye on Fed meet	03-20	RE
Aurobindo Pharma Gets US FDA Final Nod for Mometasone Furoate Monohydrate Nasal Spray	03-20	MT
Aurobindo Pharma Limited Receives Final Approval from the US Food & Drug Administration	03-19	CI
Aurobindo Pharma Arm Restarts Distribution of Aseptic Products from Unit III	03-12	MT
APL Healthcare Limited Subsidiary of Aurobindo Pharma Limited Announces Unit Inspection Team of World Health Organization Conducts an Inspection at the Unit IV	03-11	CI
Aurobindo Pharma Limited Appoints N. Ravikiran as Chief Business Officer	03-05	CI
Aurobindo Pharma Limited Receives USFDA Approval for Fingolimod Capsules, 0.5 Mg	03-01	CI
Indian shares set to rise on strong domestic growth, in-line US inflation data	03-01	RE
US FDA Completes Inspection of Aurobindo Pharma's Injectibles Unit	03-01	MT

Aurobindo Pharma specializes in the research, development, manufacturing and marketing of active pharmaceutical ingredients and generic pharmaceuticals. The group's activity is organized around 2 product families : - generic drugs: for the treatment of neurological, cardiovascular, viral, gastroenterological, ophthalmologic and chronic diseases; - active pharmaceutical ingredients. At the end of March 2018, the group operated 23 production sites in India (19), the United States (3) and Brazil. Net sales are distributed geographically as follows: India (12%), the United States (46.5%), Europe (31.2%) and other (10.3%).

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Aurobindo Pharma

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,371 INR

Average target price

1,322 INR

Spread / Average Target

-3.57%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AUROBINDO PHARMA	+22.75%	9.61B
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+32.16%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ROCHE HOLDING AG	+12.64%	250B
ASTRAZENECA PLC	+16.09%	247B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals